Institute for Molecular Bioscience
The Institute for Molecular Bioscience is a research institute within The University of Queensland that conducts molecular bioscience research across drug discovery, genomics, antimicrobial resistance, and cell biology. It serves pharmaceutical companies, healthcare systems, and the global scientific research community through grants, partnerships, and technology transfer.
- Company typePrivate
- Founded2000
- HeadquartersBrisbane, Australia
- Headcount251–500
- GTM typeB2B
- OfferingServices
Institute for Molecular Bioscience firmographics
Firmographics- Name
- Institute for Molecular Bioscience
- Legal name
- The University of Queensland
- Website
- https://imb.uq.edu.au
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- The Institute for Molecular Bioscience is a research institute within The University of Queensland that conducts molecular bioscience research across drug discovery, genomics, antimicrobial resistance, and cell biology. It serves pharmaceutical companies, healthcare systems, and the global scientific research community through grants, partnerships, and technology transfer.
- Ownership category
- akta.pro rank
Institute for Molecular Bioscience industry classification
Industry- Product category
- Biomedical Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Colleges, Universities, and Professional Schools (6113)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)
- akta.pro secondary industries
- Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Institute for Molecular Bioscience is headquartered
LocationHeadquarters
- HQ city
- Brisbane
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Institute for Molecular Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Research Grants: Funded primarily through competitive research grants from government bodies including the National Health and Medical Research Council (NHMRC) and Australian Research Council (ARC)
- Corporate Partnerships: Corporate partnerships and collaborations with pharmaceutical and biotechnology companies for research and development
- Technology Transfer: Translation of research into commercial outcomes including drugs in clinical trials, insecticides for agricultural applications, and animal baits for pest control
Distribution channels3 records
Marketing channels4 records
Institute for Molecular Bioscience product offering
Product offeringCore offering
The Institute for Molecular Bioscience (IMB) is a research institute within the University of Queensland that conducts fundamental and applied research in molecular bioscience. It operates multiple research centres focused on translating scientific discoveries into therapeutic and commercial outcomes, spanning drug discovery, genomics, proteomics, and bioinformatics. The institute is funded by grants (NHMRC, ARC), corporate partnerships, and technology transfer/licensing.
Product overview
The Institute for Molecular Bioscience (IMB) is a research institute within the University of Queensland that conducts molecular bioscience research. Rather than a unified commercial product, IMB operates as a portfolio of four specialized research centres: the Centre for Population & Disease Genomics (focused on statistical and systems genomics for disease treatment), the Centre for Chemistry and Drug Discovery (developing precision drugs from natural sources), the Centre for Superbug Solutions (combating antimicrobial resistance through diagnostics and treatments), and the Centre for Cell Biology and Chronic Disease (studying cellular mechanisms of chronic diseases like cancer). These centres are supported by multiple research groups and produce publications including The Edge Magazine. The institute translates research into clinical applications including drugs in clinical trials, insecticides, and animal baits for pest control.
Differentiator
Problem solved
Functional benefit
Products and services
- Research Centres (4 centres)
Quantifiable outcome
- Drug in clinical trials for heart disease based on funnel-web venom
- +2 more outcomes
Companies that use Institute for Molecular Bioscience
Customer profileSegments3 records
Ideal customer profiles2 records
Institute for Molecular Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Institute for Molecular Bioscience partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Corporate PartnerscoreCorporate partnerships program allowing companies to collaborate with IMB researchers on drug discovery, diagnostics, and other research initiatives. Partners can engage through the 'Partner with us' program.
- QIMRB (QIMR Berghofer Medical Research Institute)coreCollaboration with clinical scientists on chronic liver disease research, particularly with Professor Elizabeth Powell at the PA Hospital
- Mater ResearchcoreCollaboration with biomedical scientists including Kate Irvine on liver fibrosis and inflammatory disease research
- Cedars Sinai, Los AngelesminorInternational collaboration with biomedical scientist Ekihiro Seki on chronic liver disease research
- Child Health Research Centre UQcoreCollaboration on Cystic Fibrosis research with clinicians Peter Sly and Paul Robinson focusing on anti-infective approaches
- Children's Health Queensland Hospital and Health ServicecoreClinical collaboration with Professor Claire Wainwright on treating infections in people with Cystic Fibrosis
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Institute for Molecular Bioscience competitors and assessment
Company assessmentRegional players
- European Molecular Biology Laboratory (EMBL): Intergovernmental molecular biology research organisation headquartered in Heidelberg with pan-European sites. Comparable in molecular bioscience research scope and translational orientation, but operating across Europe rather than Australia.
Direct peers
- Centenary Institute: Sydney-based medical research institute focused on inflammation, infectious disease and cancer. Comparable in size, university-adjacent model, and translational drug discovery orientation to IMB.
- Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's largest medical research institute, based in Melbourne. Like IMB, WEHI conducts fundamental molecular biology and translational research across cancer, infectious disease and immunology, with analogous grant funding and pharma partnership models.
- Garvan Institute of Medical Research: Sydney-based biomedical research institute with parallel genomics, cell biology and translational programmes. Highly comparable in scale, funding mix (NHMRC/grants) and disease-area focus to IMB.
- Peter MacCallum Cancer Centre: Australia's leading cancer research and treatment centre, with strong translational and clinical-trial pipelines. Comparable to IMB's Centre for Cell Biology and Chronic Disease in scale and translational mission.
- QIMR Berghofer Medical Research Institute: Brisbane-based medical research institute with formal collaboration history with IMB. Direct regional peer with comparable infectious-disease, genomics and translational research scope.
Broad incumbents
- MRC Laboratory of Molecular Biology: UK-based, globally leading molecular biology research institute. Highly comparable in molecular bioscience focus and Nobel-tier discovery track record, though with substantially greater scale and legacy.
- Karolinska Institutet: Sweden's premier medical university with extensive biomedical and translational research. Comparable in university-anchored model and broad biomedical research portfolio, though substantially larger and more clinically integrated.
- The Scripps Research Institute: Major US non-profit biomedical research organisation with broad drug discovery programmes. Comparable to IMB in translational chemistry/drug discovery orientation but at much greater scale and longer commercial track record.
- Broad Institute of MIT and Harvard: US-based, substantially larger genomics and biomedical research institute. Comparable in genomics methodology leadership and translational pipelines but with materially greater scale and funding.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Institute for Molecular Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Institute for Molecular Bioscience leadership team
Management profileNumber of profiles
Institute for Molecular Bioscience subsidiaries and ownership
Company hierarchySubsidiaries4 records
Institute for Molecular Bioscience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Institute for Molecular Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Institute for Molecular Bioscience
What does Institute for Molecular Bioscience do?
The Institute for Molecular Bioscience (IMB) is a research institute within the University of Queensland that conducts fundamental and applied research in molecular bioscience. It operates multiple research centres focused on translating scientific discoveries into therapeutic and commercial outcomes, spanning drug discovery, genomics, proteomics, and bioinformatics. The institute is funded by grants (NHMRC, ARC), corporate partnerships, and technology transfer/licensing.
Is Institute for Molecular Bioscience a public or private company?
Institute for Molecular Bioscience is a private company. It is classified as state government owned and is currently operating.
When was Institute for Molecular Bioscience founded?
Institute for Molecular Bioscience was founded in 2000. It employs 251 to 500 people.
Where is Institute for Molecular Bioscience based?
Institute for Molecular Bioscience is headquartered in Brisbane, Australia, in the Oceania region.
How does Institute for Molecular Bioscience make money?
Three revenue lines are on record. Research Grants are the primary driver. The others are corporate Partnerships and technology Transfer.
Who are Institute for Molecular Bioscience's main competitors?
European Molecular Biology Laboratory (EMBL) is listed as a regional player. Direct peers are Centenary Institute, Walter and Eliza Hall Institute of Medical Research (WEHI), Garvan Institute of Medical Research, Peter MacCallum Cancer Centre and QIMR Berghofer Medical Research Institute. Broad incumbents are MRC Laboratory of Molecular Biology, Karolinska Institutet, The Scripps Research Institute and Broad Institute of MIT and Harvard.
Does Institute for Molecular Bioscience have an API?
No public API is recorded for Institute for Molecular Bioscience.
What industry is Institute for Molecular Bioscience in?
Institute for Molecular Bioscience's product category is Biomedical Research. Its primary akta.pro industry code is EDAHAGAI, Biomedical Sciences & Medical Research Institutes (University-Based), with a secondary code of HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 541714 and its SIC code is 8731.